Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD

Post-traumatic stress disorder (PTSD) is a significant public‑health problem among military veterans and first responders, producing occupational, relational and psychological dysfunction, reduced quality of life, and increased suicide risk. While multiple pharmacological and psychotherapeutic treatments exist, a substantial group remains treatment‑resistant. Multidisciplinary Association for Psychedelic Studies (MAPS)-sponsored Phase II trials have investigated MDMA-assisted psychotherapy in such populations, typically using the Clinician Administered PTSD Scale (CAPS‑IV) as the primary quantitative efficacy measure. The authors argue that CAPS‑IV captures frequency and intensity of core PTSD symptoms but does not encompass broader quality‑of‑life changes or nuanced experiential outcomes that may follow this intervention. Barone and colleagues report a long‑term qualitative follow‑up of participants from a Phase II MDMA-assisted psychotherapy trial for military veterans and first responders. Their aim was to complement and expand upon CAPS‑IV and Long‑Term Follow‑Up (LTFU) questionnaire results by identifying thematic elements of participants’ experiences before, during and after treatment, thereby illuminating perceived benefits that lie beyond symptom reduction.

This retrospective qualitative study used semi‑structured interviews conducted at the one‑year LTFU visit of a Phase II, randomized, double‑blind, crossover clinical trial of MDMA‑assisted psychotherapy for treatment‑resistant PTSD. The original clinical trial included a low‑dose (active control), medium‑dose and full‑dose arm; after unblinding, participants in control or medium arms were offered three open‑label full‑dose MDMA sessions to match the full‑dose group. Weekly non‑drug therapy sessions were provided throughout. Experimental sessions occurred monthly and consisted of six‑to‑eight‑hour manualised MDMA‑assisted psychotherapy delivered by a male–female co‑therapy team using a relatively non‑directive, client‑directed approach. Interviews were designed by a member of the research team (JB) based on the LTFU Questionnaire and were conducted by one or both trial therapists during the one‑year follow‑up visit. The semi‑structured format followed the questionnaire while allowing open discussion of topics participants deemed important; this timing was intended to provide reflective perspective and to permit comparison with contemporaneous CAPS‑IV and LTFU questionnaire data. Nineteen interviews were recorded and transcribed for analysis. A four‑member team performed thematic analysis using an Interpretative Phenomenological Analysis (IPA) framework. An initial codebook was developed by two researchers (WB and JB) from the first three transcripts, combining top‑down codes derived from interview questions with bottom‑up codes emerging from the data; temporal coding (before, during, after treatment) was included where relevant. Each transcript was coded by at least two researchers, with pooled inter‑rater reliability assessed by Cohen’s kappa (≥ 0.75). Weekly team meetings were used to harmonise coding and revise the codebook, and ATLAS.ti 8.2.4 was used to organise codes, identify co‑occurrences and search across participants. Eligible participants were adults (over 18) who were military veterans, police or firefighters with a CAPS‑IV total score ≥ 50 (indicating moderate to severe PTSD) and who met the study’s definition of treatment‑resistant (failure to respond to or inability to tolerate more than one adequate psychotherapeutic or psychopharmacological treatment). Of 26 original trial enrolees, 24 completed the study and one‑year LTFU assessment; 19 of those had recorded qualitative interviews available for analysis. The analysed cohort comprised 16 veterans, two firefighters and one police officer, including 13 men and six women aged 24–56. The extracted text references figures and tables for additional details but those displays are not included here.

Quantitatively, within the analysed sample 15 of 19 participants (79%) showed clinically significant reductions in PTSD symptoms at one‑year follow‑up, defined as >30% reduction in CAPS‑IV total scores from baseline; the average CAPS‑IV change reported in the extract was 68% from baseline. The qualitative dataset revealed that all interviewed participants reported lasting personal benefits and enhanced quality of life that extended beyond symptom counts. Thematic analysis identified recurring outcome domains. Improved self‑awareness was described by all participants (n = 19); interviewees reported gaining insights into personal beliefs, triggers and patterns, and many described increased self‑compassion and better ability to recognise and manage symptoms. Several participants who showed minimal CAPS‑IV change nonetheless described substantial shifts in self‑understanding (for example, Participant 819: "I learned a lot about myself"). Improved relationships and social functioning were reported by a majority (n = 12). Participants described enhanced communication, greater empathy and repair or strengthening of family relationships. Engagement in new activities and increased motivation appeared across the full sample (n = 19), with examples including renewed creative pursuits, social re‑engagement and a stronger desire to ‘‘make up for lost time.’' Thirteen participants reported reductions in reliance on prescription medication and problematic substance use; nine recalled prior extensive substance use for coping. Examples include large decreases in alcohol consumption and cessation or reduction of multiple medications. Fourteen participants described increased openness to future therapies after the MDMA‑assisted treatment, reporting that MDMA helped them break defensive barriers that had limited benefit from prior therapies. Participants also highlighted perceived therapeutic factors integral to outcomes: the pharmacological effects of MDMA in facilitating processing, the preparatory and integration psychotherapy sessions, and strong rapport with the therapy team. These elements were often described as synergistic—MDMA reduced fear or reactivity during memory processing within a safe therapeutic setting, which, combined with therapist support, accelerated therapeutic progress. The extract does not report adverse events, detailed subgroup statistics beyond the counts above, or full quantitative tables; it refers readers to other reports for a comprehensive quantitative long‑term outcome analysis. Additionally, five LTFU interviews were not available for analysis because they were not recorded or were inaccessible at time of analysis.

Barone and colleagues interpret their findings as evidence that MDMA‑assisted psychotherapy can produce durable improvements in PTSD symptoms while also engendering broader quality‑of‑life changes that CAPS‑IV scores alone do not capture. They emphasise that participant narratives provide context to outcome measures and illustrate benefits across self‑awareness, relationships, activity engagement, substance use reduction and receptivity to further treatment. The authors point out cases where minimal CAPS‑IV improvement coincided with meaningful qualitative gains, underscoring the limitations of relying solely on symptom scales to judge treatment impact. Several methodological limitations and uncertainties are acknowledged. Conducting the qualitative study within an existing trial constrained protocol choices. Having trial therapists conduct the interviews—while advantageous for rapport, safety and logistics—may have constrained candidness or steered conversations in particular directions; this preexisting relationship could both elicit memories otherwise unrecalled and limit negative feedback. Five participant interviews were excluded because they were not recorded or unavailable, reducing the analysed sample. Demographic representation was limited: the cohort was predominantly male and largely White/Caucasian, which may affect transferability of findings across race, gender, age, ability or socioeconomic groups. The authors recommend improvements for future qualitative work nested in clinical trials. They suggest collecting qualitative data at multiple timepoints (pre‑treatment, post‑treatment and long‑term follow‑up) to capture evolving experiences, and using independent interviewers with no prior contact to reduce potential bias and encourage freer discussion of concerns. Evaluating outcomes across different therapy teams is also advised to disentangle the effects of therapeutic relationship from the medication. The discussion situates these qualitative findings alongside the broader evidentiary trajectory: durable CAPS‑IV improvements in Phase II trials contributed to the FDA’s Breakthrough Therapy designation for MDMA‑assisted psychotherapy and progression to Phase III trials. Finally, the authors assert that qualitative approaches are valuable for honouring participant perspectives and for enriching understanding of therapeutic benefits as multi‑site trials expand.